Basic information Description In vitro In vivo Safety Related Supplier
ChemicalBook >  Product Catalog >  Biochemical Engineering >  Inhibitors >  GPCR & G Protein >  CXCR antagonist >  PLERIXAFOR

PLERIXAFOR

Basic information Description In vitro In vivo Safety Related Supplier
PLERIXAFOR Basic information
PLERIXAFOR Chemical Properties
  • Melting point:122-125°C
  • Boiling point:657.5±55.0 °C(Predicted)
  • Density 0.962
  • storage temp. Refrigerator
  • pka10.60±0.20(Predicted)
  • CAS DataBase Reference110078-46-1
Safety Information
  • HS Code 29339900
PLERIXAFOR Usage And Synthesis
  • DescriptionPlerixafor (AMD3100) is a chemokine receptor antagonist for CXCR4 and CXCL12-mediated chemotaxis with IC50 of 44 nM and 5.7 nM in cell-free assays, respectively.
  • In vitroPlerixafor inhibits CXCL12-mediated chemotaxis with a potency lightly better than its affinity for CXCR4. Plerixafor also antagonizes SDF-1/CXCL12 ligand binding with an IC50 of 651 nM. Plerixafor inhibits SDF-1 mediated GTP-binding, SDF-1 mediated calcium flux and SDF-1 stimulated chemotaxis with IC50 of 27 nM, 572 nM and 51 nM, respectively. Plerixafor does not inhibit calcium flux against cells expressing CXCR3, CCR1, CCR2b, CCR4, CCR5 or CCR7 when stimulated with their cognate ligands, nor does Plerixafor inhibit receptor binding of LTB4. Plerixafor does not, on its own, induce a calcium flux in the CCRF–CEM cells, which express multiple GPCRs including CXCR4, CCR4 and CCR7.
  • In vivoA single topical application of Plerixafor promotes wound healing in diabetic mice by increasing cytokine production, mobilizing bone marrow EPCs, and enhancing the activity of fibroblasts and monocytes/macrophages, thereby increasing both angiogenesis and vasculogenesis. Cohorts of mice are administered with PBS, IGF1, PDGF, SCF, or VEGF for five consecutive days and Plerixafor on the 5th day. The number and size of the colonies are highest in IGF1 plus Plerixafor injected mice compared to PDGF, SCF and VEGF treated groups, in combination with Plerixafor.
  • DescriptionAutologous hematopoietic stem cell (HSC) transplantation, a standard treatment for hematological malignancies, such as non-Hodgkin’s lymphoma or multiple myeloma, involves collection of HSCs from the patient, chemo- or radiotherapy of the patient to eliminate malignant cells, and retransplantation of the stored HSCs.
    Plerixafor is a potent antagonist of the CXCR4 chemokine receptor and a first-in-class drug for stem cell mobilization. CXCR4 is specific for stromal-derived-factor-1 (SDF-1), a molecule endowed with potent chemotactic activity forlymphocytes. Because the interaction between SDF-1 and CXCR4 plays an important role in holding HSCs in the bone marrow, drugs that block the activity of CXCR4 receptor are capable of mobilizing HSCs into the bloodstream. In vitro, plerixafor potently blocks SDF-1 binding of CXCR4 and inhibits SDF-1-induced calcium flux (IC50 = 0.01-0.13 mg/mL) and chemotaxis (IC50 = 0.13 mg/mL) in several different cell types. Plerixafor, in combination with G-CSF, is specifically indicated to mobilize HSCs to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin’s lymphoma and multiple myeloma.
  • Chemical PropertiesWhite Solid
  • OriginatorAnorMED (Canada)
  • UsesPlerixafor is a chemokine receptor antagonist for CXCR4 and CXCL12-mediated chemotaxis with IC50 of 44 nM and 5.7 nM, respectively
  • UsesPlerixafor is a hematopoietic stem cell (HSC) mobilizer that inhibits the CXCR4 chemokine receptor and blocks binding of its ligand, stromal cell-derived factor-1-α (SDF-1-α). on Dec. 15, 2008, as treatment in combination with granulocyte-colony stimulating factor (G-CSF) to mobilize HSCs to the peripheral blood for collection and subsequent autologous transplantation in p atients with non-Hodgkin's lymphoma (NHL) and multiple myeloma (MM).
  • brand nameMozobil
  • Side effectsThe most common adverse reactions (occurring in more than 10% of patients) observed during plerixafor use include diarrhea, nausea, fatigue, injection-site reactions, headache, arthralgia, dizziness, and vomiting.
  • Chemical SynthesisPlerixafor can be synthesized by several related procedures starting from tetraazacyclotetradecane, the macrocyclic tetraamine cyclam. The general synthetic strategy entails the masking of three of the four ring nitrogens, followed by alkylation with para-xylylene dibromide, and subsequent removal of the masking groups. In one approach, tetraazacyclotetradecane is protected as the phosphorotriamide derivative by reaction with tris (dimethylamino)phosphine followed by oxidation with carbon tetrachloride and sodium hydroxide. After condensation with xylylene dibromide, the dimeric bis-phosphoramide intermediate is hydrolyzed to plerixafor by treatment with dilute hydrochloric acid solution.
PLERIXAFOR(110078-46-1)Related Product Information
PLERIXAFORSupplierMore
  • Company Name:Lihe Wuhan New Chemical Materials Co., Ltd. Gold
  • Tel:027-88395709,15071332665
  • Email:gjing@51chemall.com
  • Products Intro:Product Name:PLERIXAFOR
    CAS:110078-46-1
    Purity:99
  •  
  • Company Name:Wuhan Boye Technology Development Co., Ltd. Gold
  • Tel:15327148496 027-81625225-
  • Email:1973211433@qq.com
  • Products Intro:Product Name:PLERIXAFOR
    CAS:110078-46-1
    Purity:99.50%
  •  
  • Company Name:Wuhan Sunrise Technology Development Co., Ltd. Gold
  • Tel:13554138826
  • Email:whsrtech@vip.163.com;whsrtech@vip.163.com
  • Products Intro:Product Name:Plerixafor
    CAS:110078-46-1
    Purity:99 Package:20g Remarks:used for research only
  •  
  • Company Name:Shanghai Boyle Chemical Co., Ltd.
  • Tel:
  • Email:sales@boylechem.com
  • Products Intro:Product Name:PLERIXAFOR
    CAS:110078-46-1
  •  
  • Company Name:J & K SCIENTIFIC LTD.
  • Tel:400-666-7788 010-82848833-
  • Email:jkinfo@jkchemical.com;market6@jkchemical.com
  • Products Intro:Product Name:Plerixafor, 99%
    CAS:110078-46-1
    Purity:99% Package:100MG;25MG;5MG
  •